Evidence map›Paper›PMID 28972182›Full record

ArticleThe Journal of biological chemistry2017

Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.

Victoria Stepanova, Konstantin V Dergilev, Kelci R Holman, Yelena V Parfyonova, Zoya I Tsokolaeva, Mimi Teter, Elena N Atochina-Vasserman, Alla Volgina, Sergei V Zaitsev, Shane P Lewis and 4 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Victoria StepanovaFrom the Department of Pathology and Laboratory Medicine and vstepano@pennmedicine.upenn.edu.
Konstantin V Dergilevthe Angiogenesis Laboratory, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Moscow 121552, Russia.
Kelci R Holmanthe College of Arts and Sciences, Drexel University, Philadelphia, Pennsylvania 19104, and.
Yelena V Parfyonovathe Angiogenesis Laboratory, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Moscow 121552, Russia.
Zoya I Tsokolaevathe Angiogenesis Laboratory, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Moscow 121552, Russia.
Mimi Teterthe College of Arts and Sciences, Drexel University, Philadelphia, Pennsylvania 19104, and.
Elena N Atochina-VassermanPenn Center for Pulmonary Biology, Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104.
Alla VolginaPenn Center for Pulmonary Biology, Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104.
Sergei V ZaitsevFrom the Department of Pathology and Laboratory Medicine and.
Shane P Lewisthe College of Arts and Sciences, Drexel University, Philadelphia, Pennsylvania 19104, and.
Fedor G Zabozlaevthe Department of Pathology, Federal Research Clinical Center Federal Medical and Biological Agency of Russia, Moscow 115682, Russia.
Kseniya ObraztsovaPenn Center for Pulmonary Biology, Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104.
Vera P KrymskayaPenn Center for Pulmonary Biology, Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104.
Douglas B CinesFrom the Department of Pathology and Laboratory Medicine and.
University of Pennsylvania · USDrexel University · USNational Medical Research Center of Cardiology · RUPhiladelphia University · USFederal Medical-Biological Agency · RU

Funding

Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)R01HL131626 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KRYMSKAYA, VERA P · 2016 to 2019
$2.6M
TSC signaling and pulmonary LAMR01HL114085 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KRYMSKAYA, VERA P · 2012 to 2015
$1.9M
Prevention and management of perioperative pulmonary embolismR01HL116916 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CINES, DOUGLAS BROCK, MUZYKANTOV, VLADIMIR R · 2013 to 2016
$1.6M
NHLBI NIH HHS R01 HL114085NHLBI NIH HHS R01 HL116916NHLBI NIH HHS R01 HL131626
6 · The paper itself

Abstract

Lymphangioleiomyomatosis (LAM) is a fatal lung disease associated with germline or somatic inactivating mutations in tuberous sclerosis complex genes (

Indexed as

MutationAngiomyolipomaAnimalsAntineoplastic AgentsApoptosisCell Line, TumorGene Expression Regulation, NeoplasticHumansKidney NeoplasmsLungLung NeoplasmsLymphangioleiomyomatosisMice, Inbred C57BLMice, KnockoutNeoplasm InvasivenessNeoplasm ProteinsAntineoplastic AgentsNeoplasm ProteinsTSC1 protein, humanTsc1 protein, mouseTSC2 protein, humanTsc2 protein, mouseTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsUrokinase-Type Plasminogen Activatorlungmammalian target of rapamycin (mTOR)mTOR complex (mTORC)plasminogenTOR complex (TORC)tuberous sclerosis complex (TSC)tumor cell biologyurokinase receptor

Identifiers

PMID28972182
PMCPMC5733590
OpenAlexW2759213384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.